rs147484110
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PVS1_StrongPM2PP3_StrongPP5
The NM_000100.4(CSTB):c.67-1G>C variant causes a splice acceptor change. The variant allele was found at a frequency of 0.000298 in 1,612,442 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000100.4 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CSTB | NM_000100.4 | c.67-1G>C | splice_acceptor_variant | ENST00000291568.7 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CSTB | ENST00000291568.7 | c.67-1G>C | splice_acceptor_variant | 1 | NM_000100.4 | P1 | |||
CSTB | ENST00000640406.1 | c.67-1G>C | splice_acceptor_variant | 2 | |||||
CSTB | ENST00000639959.1 | c.36-430G>C | intron_variant | 5 | |||||
CSTB | ENST00000675996.1 | n.492-1G>C | splice_acceptor_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes ? AF: 0.000263 AC: 40AN: 152218Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000151 AC: 38AN: 251426Hom.: 0 AF XY: 0.000155 AC XY: 21AN XY: 135906
GnomAD4 exome AF: 0.000302 AC: 441AN: 1460106Hom.: 0 Cov.: 29 AF XY: 0.000300 AC XY: 218AN XY: 726556
GnomAD4 genome ? AF: 0.000263 AC: 40AN: 152336Hom.: 0 Cov.: 33 AF XY: 0.000215 AC XY: 16AN XY: 74488
ClinVar
Submissions by phenotype
Unverricht-Lundborg syndrome Pathogenic:6Uncertain:1Other:2
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Apr 29, 2021 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 22, 1996 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Aug 31, 2018 | The CSTB c.67-1G>C variant occurs in a canonical splice site (acceptor) and is therefore predicted to disrupt or distort the normal gene product. Across a selection of the literature, the c.67-1G>C variant has been identified in a compound heterozygous state in at least seven individuals with Unverricht-Lundborg disease (ULD) from six families and in one additional family where zygosity was not specified (Pennacchio et al. 1996; Joensuu et al. 2007 and Canafoglia et al. 2012). The c.67-1G>C variant was most commonly identified in a compound heterozygous state with the expanded dodecamer repeat variant, which is the most common pathogenic variant associated with ULD. Bespalova et al. (1997) analyzed mRNA transcripts from heterozygous individuals carrying the c.67-1G>C variant. RT-PCR of total mRNA showed an aberrant, shorter transcript created as a result of skipping of exon 2, confirming that the c.67-1G>C variant disrupts normal splicing and results in expression of a truncated protein. The c.67-1G>C variant was absent from at least 95 unaffected control individuals and is reported at a frequency of 0.000347 in the European (non-Finnish) population of the Genome Aggregation Database. Based on the evidence, the c.67-1G>C variant is classified as pathogenic for Unverricht-Lundborg disease. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
not provided, no classification provided | phenotyping only | GenomeConnect - Brain Gene Registry | - | Variant interpreted as Pathogenic and reported on 02-23-2021 by lab or GTR ID 239772. Assertions are reported exactly as they appear on the patient provided laboratory report. GenomeConnect does not attempt to reinterpret the variant. The IDDRC-CTSA National Brain Gene Registry (BGR) is a study funded by the U.S. National Center for Advancing Translational Sciences (NCATS) and includes 13 Intellectual and Developmental Disability Research Center (IDDRC) institutions. The study is led by Principal Investigator John Constantino MD PhD from Washington University. The BGR is a data commons of gene variants paired with subject clinical information. This database helps scientists learn more about genetic changes and their impact on the brain and behavior. Participation in the Brain Gene Registry requires participation in GenomeConnect. More information about the Brain Gene Registry can be found on the study website - https://braingeneregistry.wustl.edu/. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 26, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Dec 06, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Pathogenic, criteria provided, single submitter | research | HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology | Oct 13, 2016 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 10, 2022 | Published studies in a patient who was compound heterozygous for this variant and an expansion variant demonstrated that the level of CSTB mRNA was diminished compared to controls, and no protein was detected on Western blot (Joensuu et al., 2007); Canonical splice site variant expected to result in aberrant splicing, although in the absence of functional evidence the actual effect of this sequence change is unknown.; This variant is associated with the following publications: (PMID: 18325013, 23205931, 9360639, 9054946, 25525159, 20301321, 9012407, 17003839, 29915382, 32581362, 8596935, 31589614) - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden | Nov 03, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Apr 27, 2022 | This variant is expected to severely impact normal RNA splicing, and consequently, protein structure and/or function. The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant has been identified in at least one individual with clinical features associated with this gene. In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 15, 2015 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 04, 2018 | The c.67-1G>C intronic pathogenic mutation results from a G to C substitution one nucleotide upstream from coding exon 2 of the CSTB gene. This mutation was identified in trans with other pathogenic CSTB alterations in multiple unrelated individuals with progressive myoclonus epilepsy; it was shown to result in a misspliced mRNA product with an aberrant CSTB product lacking 33 amino acids, p.V23_K56del (Pennacchio LA et al. Science, 1996 Mar;271:1731-4; Joensuu T et al. Eur. J. Hum. Genet., 2007 Feb;15:185-93; Canafoglia L et al. Epilepsia, 2012 Dec;53:2120-7). Analysis of cells from affected patients demonstrated reduced mRNA and protein levels compared to wild type (Joensuu T et al. Eur. J. Hum. Genet., 2007 Feb;15:185-93; Canafoglia L et al. Epilepsia, 2012 Dec;53:2120-7). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. - |
Chorea;C0013384:Dyskinesia Pathogenic:1
Pathogenic, no assertion criteria provided | research | NIHR Bioresource Rare Diseases, University of Cambridge | - | - - |
Encephalopathy;C1854885:Cerebral dysmyelination;C4551563:Microcephaly Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Génétique des Maladies du Développement, Hospices Civils de Lyon | - | - - |
Progressive myoclonic epilepsy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 17, 2023 | This sequence change affects an acceptor splice site in intron 1 of the CSTB gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. This variant is present in population databases (rs147484110, gnomAD 0.03%). Disruption of this splice site has been observed in individuals with Unverricht-Lundborg disease (PMID: 8596935, 9012407, 9054946, 23205931). This variant is also known as 1924G>C. ClinVar contains an entry for this variant (Variation ID: 8395). Studies have shown that disruption of this splice site results in skipping of exon 2, but is expected to preserve the integrity of the reading-frame (PMID: 9360639, 17003839, 23205931). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at